Kee Hwan Kwon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kee Hwan Kwon has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Byeongjun Kim
Department of Plastic and Reconstructive Surgery, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea
1 shared publication Geonwoo Kim
Department of Otorhinolaryngology-Head and Neck Surgery Gangdong Sacred Heart Hospital Hallym University College of Medicine 경구강 타석 제거술 설하선 절제 경구강 타석 제거술 Seoul 악하선 Korea
1 shared publicationHwikyeong Jung
Department of Otorhinolaryngology-Head and Neck Surgery Gangdong Sacred Heart Hospital Hallym University College of Medicine 경구강 타석 제거술 설하선 절제 경구강 타석 제거술 Seoul 악하선 Korea
1 shared publication- Hyeong Seop Kim
Departments of Plastic and Reconstructive Surgery, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
1 shared publication Jaemoon Sung
Department of Otorhinolaryngology-Head and Neck Surgery Gangdong Sacred Heart Hospital Hallym University College of Medicine 경구강 타석 제거술 설하선 절제 경구강 타석 제거술 Seoul 악하선 Korea
1 shared publicationJaesoon Kim
Department of Otorhinolaryngology-Head and Neck Surgery Gangdong Sacred Heart Hospital Hallym University College of Medicine 경구강 타석 제거술 설하선 절제 경구강 타석 제거술 Seoul 악하선 Korea
1 shared publication
Latest Publications
- Open Access
- 21 February 2021
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Korean Journal of Otorhinolaryngology-Head and Neck Surgery
- Vol. 64 (2) , 93-97
Clinical Comparison of Transoral Removal with Sublingual Gland Preservation versus without Sublingual Gland Preservation versus Submandibular Gland Resection for Proximal Duct Stone of Submandibular Gland: Prospective Study
Background and Objectives Proximal submandibular stone is not a rare disease. The aim of this study is to evaluate the surgical outcomes of 3 different ways to treat proximal submandibular stone: intraoral removal of stone (IORS) with sublingual gland (SLG) resection, IORS without SLG resection and submandibular gland (SMG) resection.Subjects and Method We prospectively reviewed the surgical outcomes of IORS with SLG resection group (22 patients), IORS without SLG resection group (35 patients) and SMG resection group (22 patients). To evaluate the surgical outcomes, we analyzed the location and size of stones, mean operation time, mean hospital stay, mean postoperative degree of pain based on a visual analog scale (0–10), and incidence of complications.Results There were no significant differences between the mean diameter of stones and length from the hilum to stones. The mean operation time was shorter in the IORS without SLG resection group than that in IORS without SLG resection group, and was significantly shorter than that of the SMG resection group. The mean hospital stay of the IORS without SLG resection group was also shorter than that of IORS with SLG resection group, and was significantly shorter than the SMG resection group. IORS without SLG resection group felt less pain than IORS with SLG resection group and SMG resection group. Four patients who underwent IORS without SLG resection experienced transient and mild SMG swelling, and mild paresthesia was noted on the same side. All patients recovered within 3 months. Intraoral removal of proximal SMG stones exhibited several advantages over SMG resection in terms of hospital stay, mean operation, time and postoperative pain.Conclusion Based on our results, we suggest that IORS without SLG resection be selected as the primary procedure for the removal of proximal submandibular stones rather than SMG resection.
- 21 February 2021
- Published by Korean Society of Otorhinolaryngology-Head and Neck Surgery in Korean Journal of Otorhinolaryngology-Head and Neck Surgery
- Vol. 64 (2) , 93-97
Open AccessClinical Comparison of Transoral Removal with Sublingual Gland Preservation versus without Sublingual Gland Preservation versus Submandibular Gland Resection for Proximal Duct Stone of Submandibular Gland: Prospective Study
Background and Objectives Proximal submandibular stone is not a rare disease. The aim of this study is to evaluate the surgical outcomes of 3 different ways to treat proximal submandibular stone: intraoral removal of stone (IORS) with sublingual gland (SLG) resection, IORS without SLG resection and submandibular gland (SMG) resection.Subjects and Method We prospectively reviewed the surgical outcomes of IORS with SLG resection group (22 patients), IORS without SLG resection group (35 patients) and SMG resection group (22 patients). To evaluate the surgical outcomes, we analyzed the location and size of stones, mean operation time, mean hospital stay, mean postoperative degree of pain based on a visual analog scale (0–10), and incidence of complications.Results There were no significant differences between the mean diameter of stones and length from the hilum to stones. The mean operation time was shorter in the IORS without SLG resection group than that in IORS without SLG resection group, and was significantly shorter than that of the SMG resection group. The mean hospital stay of the IORS without SLG resection group was also shorter than that of IORS with SLG resection group, and was significantly shorter than the SMG resection group. IORS without SLG resection group felt less pain than IORS with SLG resection group and SMG resection group. Four patients who underwent IORS without SLG resection experienced transient and mild SMG swelling, and mild paresthesia was noted on the same side. All patients recovered within 3 months. Intraoral removal of proximal SMG stones exhibited several advantages over SMG resection in terms of hospital stay, mean operation, time and postoperative pain.Conclusion Based on our results, we suggest that IORS without SLG resection be selected as the primary procedure for the removal of proximal submandibular stones rather than SMG resection.
- Open Access
- 20 April 2020
- Published by Korean Cleft Palate-Craniofacial Association in Archives of Craniofacial Surgery
- Vol. 21 (2) , 132-136
Primary amelanotic melanoma of the mandibular gingiva
Oral mucosal melanoma is a very rare type of malignant melanoma, the characteristics of which differ from those of cutaneous melanoma. Primary amelanotic melanoma of the mandibular gingiva, which can invade the mandibular bone, is very rare worldwide. Here, we report a case in which we performed a reconstruction of the mandible and gingiva using the fibula osteocutaneous free flap procedure to treat a patient diagnosed with a primary amelanotic melanoma of the mandibular gingiva. The procedure was successful, and no recurrence was observed 10 months after surgery. Oral mucosal melanoma has a much poorer prognosis and a lower 5-year survival rate than cutaneous melanoma. However, recently, immunomodulatory therapies for mutations in melanocytic lesions have been used effectively to treat the increasing number of patients developing this type of melanoma, thus improving the prognosis of patients with oral mucosal melanoma.
- 20 April 2020
- Published by Korean Cleft Palate-Craniofacial Association in Archives of Craniofacial Surgery
- Vol. 21 (2) , 132-136
Open AccessPrimary amelanotic melanoma of the mandibular gingiva
Oral mucosal melanoma is a very rare type of malignant melanoma, the characteristics of which differ from those of cutaneous melanoma. Primary amelanotic melanoma of the mandibular gingiva, which can invade the mandibular bone, is very rare worldwide. Here, we report a case in which we performed a reconstruction of the mandible and gingiva using the fibula osteocutaneous free flap procedure to treat a patient diagnosed with a primary amelanotic melanoma of the mandibular gingiva. The procedure was successful, and no recurrence was observed 10 months after surgery. Oral mucosal melanoma has a much poorer prognosis and a lower 5-year survival rate than cutaneous melanoma. However, recently, immunomodulatory therapies for mutations in melanocytic lesions have been used effectively to treat the increasing number of patients developing this type of melanoma, thus improving the prognosis of patients with oral mucosal melanoma.